Interstitial lung disease in the patient who has connective tissue disease
Section snippets
Review of systems
Systemic complaints are common in many diseases; a detailed history and review of systems is critical in obtaining the correct ILD diagnosis. Box 1 is a checklist of symptoms and physical examination findings that commonly are associated with an underlying connective tissue disease. Some office practices have interstitial lung disease questionnaires so that errors of omission in symptom review do not occur.
Physical examination
Physical examination findings provide important clues to diagnosis of an underlying rheumatologic condition. A careful skin examination is an essential part of the physical examination. Skin findings in early systemic sclerosis (SSc) or scleroderma may be subtle; finger swelling (puffy fingers) often is the first specific SSc manifestation. This edematous phase is followed by sclerodactyly and thickening (sclerosis) of the skin more proximally. The term “limited cutaneous SSc” refers to skin
Laboratory screening
Laboratory screening commonly is used to decide if further CTD evaluation is needed. Laboratory tests that are used for screening purposes are neither sensitive nor perfectly specific for the CTD. A Westergren sedimentation rate is elevated in many infectious, malignant, and systemic diseases. Therefore, a high value is of limited benefit. Conversely, a low value may help to exclude active CTD, although normal values can be found occasionally.
Antinuclear antibodies (ANA) are found in most
Systemic lupus erythematosus
The American College of Rheumatology (ACR) publishes and updates the criteria that are necessary to establish a diagnosis of SLE. The most common pulmonary manifestations of disease are listed in Box 2. Patients who have evolving lupus may present with pulmonary manifestations without meeting formal criteria for the diagnosis. Patients who have SLE and diffuse lung disease require bronchoscopy to rule out infection or alveolar hemorrhage. Although infection is the most common cause of diffuse
Rheumatoid arthritis
RA is characterized by a symmetrical inflammatory arthritis and has a high prevalence of extra-articular manifestations. RA-associated pulmonary abnormalities are listed in Box 4. Although ILD is common in autopsy series, the frequency of clinically-significant ILD seems to be declining because disease-modifying antirheumatologic drugs are used with higher frequency. In the recent Spanish Registry of RA, ILD had a prevalence of 3.7% when diagnosed by chest radiography [12], [19]. Most patients
Systemic sclerosis
SSc (scleroderma) is a systemic fibrotic disease of unknown etiology that presents with two clinical phenotypes: ILD occurs with the limited (CREST variant, lcSSc) and diffuse (dcSSc) variants and is now a leading cause of morbidity and mortality (Box 5). Usually, ANA is positive in both subsets of disease: anticentromere or antibodies to T0/TH are predominant in limited disease [32] and an anti-SCl-70 antibody that is present on ENA panel is found more commonly in diffuse disease and is
Polymyositis/dermatomyositis
PM is a rare muscle disease that is characterized by proximal muscle weakness. Skin lesions that consist of violaceous scaling patches, Gottron's papules, facial heliotrope rash, or mechanic's hands characterize DM. Some patients who have DM without muscle disease (amyotrophic DM) also can have lung disease [44], [45]. The presentation of PM/DM diffuse lung disease was present in 65% of new diagnoses in one recent clinical series and was clinically silent in some individuals [46]. Lung disease
Sjögren's syndrome
SS is an autoimmune exocrinopathy and an autoimmune epithelitis that is characterized by lymphoproliferation and lymphocytic infiltration of glandular and nonglandular tissue. Typically, patients present with dry mouth (xerostomia), dry eyes (keratoconjunctivitis), and arthritis. SS is a complicating factor of many CTDs (secondary Sjögren's syndrome), but also may present without other CTDs (primary Sjögren's syndrome). Pulmonary symptoms of SS include cough and dyspnea. Usually, cough is from
Mixed connective tissue disease
MCTD is an overlap syndrome that combines features of SLE, SSc, RA, and PM/DM, that is combined with the presence of ribonucleoprotein (RNP) antibodies on ENA testing. Patients who have MCTD do not meet specific criteria for another CTD, but long-term follow-up of patients showed that most developed one of the more recognized CTD entities—usually scleroderma—over the next 5 years. Undifferentiated CTD differs from MCTD because MCTD requires the presence of an antibody to RNP. If the anti-RNP is
Undifferentiated connective tissue disease
Occasionally, patients present with individual features of a CTD but fail to meet ACR entry criteria for any single disease. These patients are classified as having undifferentiated connective tissue disease (UCTD). These individuals, like those who have MCTD, usually transition to other disease entities over time [63].
There are no studies that describe adequately the appropriate treatment of ILD in this population; most experts treat according to recommendations for the CTD that is most
Cryptogenic organizing pneumonia in the connective tissue diseases
Many of the CTDs have a bronchiolar and alveolar injury pattern on biopsy that heals with a loose connective tissue matrix that fills airways and airspaces (Fig. 2). Bronchiolar manifestations are more commonly seen in RA and SS; however, any of the CTDs can have an associated bronchiolitis. An organizing pneumonia that histologically contains loose connective tissue without recognizable infection also is seen in these same diseases with bronchiolar injury. The American Thoracic
Summary
Although rheumatologists often assume primary care for patients who have CTDs, their training in lung disease physiology, determining lung disease stability, and treatment of complications of ILDs, such as bronchiectasis, hypoxemia, pulmonary hypertension, and cough, require the assistance of a pulmonary physician for optimal management. Therefore, the successful and optimal management of these complicated patients is best achieved by a collaborative approach between the pulmonary physician and
References (63)
- et al.
Connective tissue diseases and the pleura
Chest
(1993) - et al.
Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus
Semin Arthritis Rheum
(2002) - et al.
Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management
Chest
(1996) - et al.
Acute lupus pneumonitis with normal chest radiograph
Chest
(1997) - et al.
Systemic lupus erythematosus patients with respiratory symptoms: the value of HRCT
Clin Radiol
(1997) - et al.
Clinical and laboratory features of lupus patients with complicating pulmonary disease
Respir Med
(1999) - et al.
Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis
Semin Arthritis Rheum
(1993) - et al.
Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy
Chest
(1977) - et al.
Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition
Chest
(2002) - et al.
Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis
Am J Med
(1989)